Table 1 Clinical characteristics of patients enrolled in the study for the explorative phase
| Â | HV | RA |
|---|---|---|
n | 15 | 15 |
Female | 15 | 15 |
Age—mean (range) | 41 years (24–48) | 43 years (25–49) |
BMI—mean (range) | 22 (19–28) | 23 (17–36) |
Disease duration—mean (range) | – | 86 months (4–300) |
DAS28-CRP | – | 4.9 (3.6–8) |
ESR | – | 28.5 (2–67) |
CRP+ % | – | 61 |
RF+ % | – | 66 |
Anti-CCP+ % | – | 83 |
Treatment % | Â | Â |
Corticoids | – | 40 |
NSAID | – | 46 |
MTX | – | 33 |
Leflunomide | – | 13 |
Biologics | – | 40 |